Navigation Links
A Drug With Efficacy Superior to That of Memantine Would Earn up to a 50% Patient Share in the Moderate-to-Severe Alzheimer's Disease Drug Market

A Drug's Effect on Cognitive Decline is the Most Important Attribute Influencing Prescribing Decisions, According to a New Report from Decision


WALTHAM, Mass., March 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug with efficacy superior to that of sales leader memantine would earn up to a 50% patient share in the market to treat moderate-to-severe Alzheimer's disease. The currently available branded versions of memantine are Forest Laboratories' Namenda, Lundbeck's Ebixa and Merz/Grupo Grunenthal's Axura/Akatinol.

The new report entitled Alzheimer's Disease (Moderate to Severe): Incremental Improvements in Efficacy Can Lead to Large Commercial Opportunity finds that a symptomatic therapy with efficacy greater than that of memantine, as measured by the Severe Impairment Battery score at 28 weeks, would earn a patient share of 40-50% in the moderate-to-severe Alzheimer's disease market, according to surveyed neurologists. In addition to replacing memantine in most cases, physicians believe that, if such a therapy were launched, it would threaten a significant percentage of prescriptions of donepezil (Eisai/Pfizer's Aricept and Bracco's Memac) and the memantine/donepezil combination.

The report also finds that a therapy's effect on cognitive decline is the attribute that most influences the prescribing decisions of neurologists in treating moderate-to-severe Alzheimer's disease. Clinical data and interviewed experts indicate that Myriad Genetics' Flurizan, Elan/Wyeth's bapineuzumab, Medivation's Dimebon and Eli Lilly's LY-450139 all have advantages over sales- leading memantine on this attribute.

"Some agents, including Flurizan and bapineuzumab, will be used in combination with existing drugs rather than replacing them," said Nitasha Manchanda, Ph.D., analyst at Decision Resources. "Approximately one-third of the neurologists we surveyed said they will use Flurizan adjunctively and nearly half of the neurologists surveyed will use bapineuzumab as an adjunct to current therapies."

About the Report

Alzheimer's Disease (Moderate to Severe): Incremental Improvements in Efficacy Can Lead to Large Commercial Opportunity is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.


SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Radiation and drug combo helps boost efficacy of lung cancer treatment
2. Parents participation in medical decisions linked to self-efficacy
3. Study Shows Cosmetic Surgery on the Rise as Safety and Efficacy of Procedures Increase
4. New strategies with greater antitumorous efficacy
5. Review of probiotic research finds only Bifantis can claim efficacy vs. placebo for IBS symptoms
6. TyRx Pharma, Inc. Announces Presentation of Results to Benefit Women with Breast Implants (In-Vivo Efficacy Study Regarding AIGISRx DEB) at the Plastic Surgery 2007 Meeting on October, 28 2007 in Baltimore, MD
7. Clinical trial data: Safety/efficacy of concomitant formoterol fumarate/tiotropium treating COPD
8. VYVANSE trial in adult ADHD demonstrated significant efficacy within 1 week of daily treatment
9. New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis
10. Study Shows Organons Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia
11. Chroma to Present Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
Post Your Comments:
(Date:11/27/2015)... ... , ... ProSidebar: Fashion is a set of 30 kinetic edge ... video editors can easily add an informative sidebar to any FCPX production. Create ... featuring self-animating drop zones, lines, bars, and text with the ease of FCPX's drag ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by Hollywood ... issues that are presently affecting Americans. Dedicated to providing the world with a wide ... subjects consumers focus on, one episode at a time. , In the latest ...
(Date:11/27/2015)... IL (PRWEB) , ... November 27, 2015 , ... ... of the largest, most successful and prominent nonprofit healthcare organizations in the country. ... governance involvement with various organizations, and helped advance the healthcare industry as a ...
(Date:11/26/2015)... ... 26, 2015 , ... Patients at Serenity Point Recovery, a ... on Thanksgiving Day to share the things that they are most grateful for ... YouTube channel, patients displayed what they wrote on index cards, describing the things ...
(Date:11/26/2015)... ... ... The Catalent Applied Drug Delivery Institute today announced a ... selection in early phase drug development. The first of these is to be ... UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, Oxford, ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... 2015 --> ... online. The potential to save costs, improve treatment quality ... from fully exploited as yet. Here, particular emphasis is ... via mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
(Date:11/27/2015)... DUBLIN , Nov. 27, 2015 Research ... of the "Global Intrauterine Devices Market 2015-2019" ... --> In this report, the author ... intrauterine devices market for 2015-2019. To calculate the market ... of following type of products: Hormonal IUDs and copper ...
(Date:11/26/2015)... UTRECHT , Países Bajos, November 26, 2015 /PRNewswire/ ... con la terapia fotodinámica de Bremachlorin para el cáncer ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Un nuevo enfoque combina la inmunoterapia con la ...   Clinical Cancer Research . --> ...
Breaking Medicine Technology: